In an attempt to rebuild its pipeline, Ironwood Pharmaceuticals has agreed to collaborate with Cour Pharmaceuticals to develop and commercialise the latter’s investigational candidate, CNP-104, in the US. The candidate leverages Cour’s proprietary nanoparticle platform, providing an innovative treatment for patients with primary biliary cholangitis, a rare liver autoimmune disease. The deal signifies Ironwood’s first step towards rebuilding its pipeline, following a restructuring of the company and multiple clinical trial failures.